Malignant germ cell ovarian cancer (MGCOC) in the Cancer Registry of Norway (CRN): A long-term follow-up study of presentation, survival, and second cancers.

5533 Background: Significant improvements in the management of MGCOC have been achieved during the past two decades. However, data on long term risk conferred by radiation and chemotherapy is scarce. This is a long-term follow-up study of presentation, survival and second cancers. Methods: 360 female patients with histologically confirmed MGCOC, recorded in the CRN between 1953 and 2009 were identified. Patients, diagnosed before 1980 were separated from those with a diagnosis 1980+, reflecting the introduction of cis-platin based chemotherapy. Data on survival and second cancer incidence were obtained by linkage to the CRN. Cox Hazards Models and Kaplan Meier estimates were used. Results: The annual incidence doubled during the observation time. Malignant teratoma was the most common histological subtype (n = 190 [53%]), followed by dysgerminoma (n = 113 [31%]) and other non - dysgerminoma tumors (n = 57 [16%]). Over two thirds of the patients (median age 34 years [range 2-92]) had localized disease with distant disease in 23%. Before 1980 70% of 159 patients received subdiaphragmatic radiotherapy, this percentage was reduced to 24% after 1980, while chemotherapy increased from 11% to 38%. The 10 years ovarian cancer specific survival (OvCSS) (median follow-up time of 9.8 years [range: 0 - 54]) increased significantly to 93% in women treated in 1980+ compared to 62% to those with an earlier diagnosis (p <0.001) . Significant period-related improvement in OvCSS was observed independently from the extent of the disease and for all histological subtypes. Women aged >50 years had a significantly poorer OvCSS than younger ones, (HR=5.98, 95%CI [3.39 to 10.57]) adjusted for histological type and stage. A second cancer was diagnosed in 27 women, 63% of these cancers were located below the diaphragm within or close to the radiation field. Conclusions: The incidence of MGCOC is rising in Norway. We observed significant improvement of ovarian cancer specific survival after the introduction of cisplatin-based chemotherapy. The development of second cancer after treatment for MGCOC seems to be related to abdominal radiotherapy.

Download Full-text

Long-Term Follow-up of Patients with HIV-Related Diffuse Large B-Cell Lymphoma (DLBCL) Treated in the Phase II Study with Rituximab and CHOP (R-CHOP)

Blood ◽

10.1182/blood.v118.21.4980.4980 ◽

2011 ◽

Vol 118 (21) ◽

pp. 4980-4980

Author(s):

Josep-Maria Ribera ◽

Mireia Morgades ◽

Albert Oriol ◽

Eva González-Barca ◽

Pilar Miralles ◽

...

Keyword(s):

Phase Ii ◽

Opportunistic Infections ◽

Conflicts Of Interest ◽

B Cell Lymphoma ◽

Cumulative Probability ◽

Second Cancer ◽

Second Cancers ◽

Long Term Follow Up

Abstract Abstract 4980 Background and objective. In the highly active antiretroviral treatment (HAART) era R-CHOP based chemotherapy has proven to be feasible and effective in HIV-related DLBCL. However, the available information on long-term follow-up of patients in remission of lymphoma is scarce. In addition, solid tumors constitute an emerging cause of cancer in HIV-infected patients under HAART. The follow-up of patients in complete response (CR) included in a phase II clinical trial of R-CHOP every 21 days conducted by the Spanish PETHEMA, GESIDA, GELTAMO and GELCAB groups (Ribera JM et al. Br J Haematol 2007; 140: 411–419) has been analyzed. Patients and methods. Out of 81 patients included in the trial 55 patients were in CR. The following data were recorded in these patients: NHL relapse, opportunistic infections (OI) and other cancers. Cumulative probabilities of OI and second cancers, as well as overall survival (OS) and event-free survival (EFS) were calculated. Results. Median follow-up of alive patients was 6.4 yr (range: 4.6–9.5). One patient was lost of follow-up in CR, 8 relapsed, 5 had OI (meningoencephalitis [2], Pneumocystis jiroveci pneumonia [1], varicella pneumonia [1], pneumoccal pneumonia [1], esophageal candidiasis [1], and CMV colitis [1]; 2 patients suffered 2 OI during their evolution) and 5 developed a second cancer (invasive carcinoma of cervix [1], squamous lung cancer [1], lung adenocarcinoma [1], pancreatic adenocarcinoma [1], and metastatic sarcoma of unknown origin [1]). Eight-year cumulative probability for OI was 15% (95%CI: 7%-23%) and for second cancer was 12% (95%CI: 2%-22%). Fourteen patients have died: 5 due to lymphoma relapse, 3 due to OI, 4 due to second cancer and 2 due to other reasons (sudden death and assassinate). Eight-year OS probability for the 55 patients in first CR of the lymphoma was 67% (95%CI: 48%-86%) and EFS probability was 59% (95%CI: 42%-76%). Conclusions. HIV-infected patients with DLBCL treated with R-CHOP and HAART followed for long-time have a significant frequency of OI and second cancers, with impact on their survival probability. Supported in part with grants RD06/0020/1056 from RTICC, Instituto Carlos III, 36606/06 from FIPSE and P-EF/10 from FJC. Disclosures: No relevant conflicts of interest to declare.

Download Full-text

The Effect of Body Mass Index and Weight Change on Epithelial Ovarian Cancer Survival in Younger Women: A Long-Term Follow-Up Study

Journal of Women s Health ◽

10.1089/jwh.2012.3487 ◽

2012 ◽

Vol 21 (8) ◽

pp. 865-871 ◽

Cited By ~ 2

Author(s):

Crystal P. Tyler ◽

Maura K. Whiteman ◽

Lauren B. Zapata ◽

Susan D. Hillis ◽

Kathryn M. Curtis ◽

...

Keyword(s):

Ovarian Cancer ◽

Body Mass Index ◽

Weight Change ◽

Cancer Survival ◽

Younger Women ◽

Follow Up Study ◽

Long Term Follow Up ◽

Ovarian Cancer Survival

Download Full-text

Intraperitoneal Chemotherapy for Ovarian Carcinoma: Results of Long-Term Follow-Up

Journal of Clinical Oncology ◽

10.1200/jco.2002.20.3.694 ◽

2002 ◽

Vol 20 (3) ◽

pp. 694-698 ◽

Cited By ~ 41

Author(s):

Richard R. Barakat ◽

Paul Sabbatini ◽

Dharmendra Bhaskaran ◽

Margarita Revzin ◽

Alex Smith ◽

...

Keyword(s):

Ovarian Cancer ◽

Prognostic Factors ◽

Residual Disease ◽

Term Survival ◽

Long Term Survival ◽

Cox Proportional Hazard ◽

Kaplan Meier ◽

Long Term Follow Up

PURPOSE: To determine long-term survival and predictors of recurrence in a retrospective cohort of patients with epithelial ovarian cancer treated with intraperitoneal (IP) chemotherapy. PATIENTS AND METHODS: Records were reviewed of 433 patients who received IP therapy for ovarian cancer between 1984 and 1998; follow-up data were available for 411 patients. IP therapy was provided as consolidation therapy (n = 89), or for treatment of persistent (n = 310) or recurrent (n = 12) disease after surgery and initial systemic therapy; therapy usually consisted of platinum-based combination therapy. Statistical analysis included tests for associations between potential prognostic factors, and between prognostic factors and survival. Survival probabilities were estimated by Kaplan-Meier methods, and prognostic factors for survival were evaluated by a Cox proportional hazard model. RESULTS: The mean age of patients was 52 years (range, 25 to 76 years). Distribution by stage and grade was as follows: stage I, 7; II, 24; III, 342; IV, 52; not available (NA), 8; and grade 1, 30; 2, 99; and 3, 289; NA, 15. The median survival from initiation of IP therapy by residual disease was none, 8.7 years; microscopic, 4.8 years; less than 1 cm, 3.3 years; more than 1 cm, 1.2 years. In a multivariate analysis, the only significant predictors of long-term survival were grade and size of residual disease at initiation of IP therapy. CONCLUSION: Prolonged survival was observed in selected patients receiving IP platinum-based therapy. It is not possible to determine the contribution of IP therapy to survival in this study. A relationship between size of disease at the initiation of IP therapy and long-term survival was demonstrated.

Download Full-text